No Data
No Data
Shuttle Pharma's Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as Reported in PLOS ONE
GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), ("Shuttle Pharma"), a discovery and development stage specialty pharmaceutical company focused on improving
Express News | Shuttle Pharmaceuticals Appoints Timothy J. Lorber As Chief Financial Officer; Part-Time Role Transitioning To Full-Time On September 10, 2024
Express News | Shuttle Pharmaceuticals: Michael Vander Hoek Will Be Transitioning Out of His Role as Chief Financial Officer
Express News | Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Press Release: Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer
Shuttle Pharma Appoints Timothy Lorber as Chief Financial Officer Current CFO, Michael Vander Hoek, transitions to full-time Vice President, Regulatory GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWI
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersReshape Lifesciences (NASDAQ:RSLS) shares rose 88.9% to $0.39 during Tuesday's after-market session. The market value of their outstanding shares is at $9.2 million. Dermata Therapeutics (NASDA
No Data
potsy52 : What entry are you
for?
Jaguar8OP potsy52: Less than 0.4. FINTEL shows it has not yet been fully covered. It’s Friday but I don’t expect full covering bec CTB is low.
Jaguar8OP potsy52: If it breaks that 0.4 50k, it will still go down